267 related articles for article (PubMed ID: 12438346)
1. Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.
Hoft DF; Eickhoff CS
Infect Immun; 2002 Dec; 70(12):6715-25. PubMed ID: 12438346
[TBL] [Abstract][Full Text] [Related]
2. Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.
Giddings OK; Eickhoff CS; Sullivan NL; Hoft DF
Infect Immun; 2010 Mar; 78(3):1333-8. PubMed ID: 20048046
[TBL] [Abstract][Full Text] [Related]
3. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
Schnapp AR; Eickhoff CS; Sizemore D; Curtiss R; Hoft DF
Infect Immun; 2002 Sep; 70(9):5065-74. PubMed ID: 12183554
[TBL] [Abstract][Full Text] [Related]
4. Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi.
Hoft DF; Schnapp AR; Eickhoff CS; Roodman ST
Infect Immun; 2000 Jan; 68(1):197-204. PubMed ID: 10603388
[TBL] [Abstract][Full Text] [Related]
5. Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.
Hoft DF; Eickhoff CS
Infect Immun; 2005 Aug; 73(8):4934-40. PubMed ID: 16041007
[TBL] [Abstract][Full Text] [Related]
6. Deficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion.
Sullivan NL; Eickhoff CS; Sagartz J; Hoft DF
J Immunol; 2015 Feb; 194(4):1806-18. PubMed ID: 25595788
[TBL] [Abstract][Full Text] [Related]
7. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
[TBL] [Abstract][Full Text] [Related]
8. Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection.
Eickhoff CS; Giddings OK; Yoshida N; Hoft DF
Mem Inst Oswaldo Cruz; 2010 Aug; 105(5):687-91. PubMed ID: 20835618
[TBL] [Abstract][Full Text] [Related]
9. Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.
Schnapp AR; Eickhoff CS; Scharfstein J; Hoft DF
Microbes Infect; 2002 Jul; 4(8):805-13. PubMed ID: 12270727
[TBL] [Abstract][Full Text] [Related]
10. Gastric invasion by Trypanosoma cruzi and induction of protective mucosal immune responses.
Hoft DF; Farrar PL; Kratz-Owens K; Shaffer D
Infect Immun; 1996 Sep; 64(9):3800-10. PubMed ID: 8751932
[TBL] [Abstract][Full Text] [Related]
11. Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
Cazorla SI; Frank FM; Becker PD; Corral RS; Guzmán CA; Malchiodi EL
Vaccine; 2008 Apr; 26(16):1999-2009. PubMed ID: 18342408
[TBL] [Abstract][Full Text] [Related]
12. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
[TBL] [Abstract][Full Text] [Related]
13. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
Basso B; Marini V
Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
[TBL] [Abstract][Full Text] [Related]
14. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice.
Martinez-Campos V; Martinez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Seid CA; Hudspeth EM; Wei J; Liu Z; Kwityn C; Hammond M; Ortega-López J; Zhan B; Hotez PJ; Bottazzi ME; Dumonteil E
Vaccine; 2015 Aug; 33(36):4505-12. PubMed ID: 26192358
[TBL] [Abstract][Full Text] [Related]
15. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
[TBL] [Abstract][Full Text] [Related]
16. Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.
Silveira EL; Claser C; Haolla FA; Zanella LG; Rodrigues MM
Clin Vaccine Immunol; 2008 Aug; 15(8):1292-300. PubMed ID: 18579696
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
Gupta S; Garg NJ
PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
[TBL] [Abstract][Full Text] [Related]
18. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
Bhatia V; Garg NJ
Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
[TBL] [Abstract][Full Text] [Related]
19. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes.
Frank FM; Petray PB; Cazorla SI; Muñoz MC; Corral RS; Malchiodi EL
Vaccine; 2003 Dec; 22(1):77-86. PubMed ID: 14604574
[TBL] [Abstract][Full Text] [Related]
20. Costimulatory Effects of an Immunodominant Parasite Antigen Paradoxically Prevent Induction of Optimal CD8 T Cell Protective Immunity.
Eickhoff CS; Zhang X; Vasconcelos JR; Motz RG; Sullivan NL; O'Shea K; Pozzi N; Gohara DW; Blase JR; Di Cera E; Hoft DF
PLoS Pathog; 2016 Sep; 12(9):e1005896. PubMed ID: 27642757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
